U.S. markets close in 3 hours 7 minutes

PDL BioPharma, Inc. (PDLI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1950-0.0150 (-0.68%)
As of 12:51PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.2100
Open2.2200
Bid2.1900 x 3000
Ask2.2000 x 2900
Day's Range2.1500 - 2.2200
52 Week Range2.1300 - 3.8600
Volume199,252
Avg. Volume1,063,366
Market Cap250.19M
Beta (5Y Monthly)0.89
PE Ratio (TTM)N/A
EPS (TTM)-1.3240
Earnings DateNov 04, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 02, 2016
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • PDL BioPharma Enters Oversold Territory
    Zacks

    PDL BioPharma Enters Oversold Territory

    PDL BioPharma has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • PDL BioPharma Completes Spin-Off of LENSAR
    PR Newswire

    PDL BioPharma Completes Spin-Off of LENSAR

    PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has completed the previously announced spin-off of its femtosecond laser system business, LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR").

  • PDL BioPharma to Complete Spin-Off of LENSAR, Inc. on October 1, 2020
    PR Newswire

    PDL BioPharma to Complete Spin-Off of LENSAR, Inc. on October 1, 2020

    PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced that its Board of Directors has approved the separation of LENSAR, Inc. ("LENSAR"), a majority owned subsidiary of PDL, from PDL in the form of a dividend involving the distribution of all outstanding shares of LENSAR common stock owned by PDL to holders of PDL common stock. Under the terms of the distribution: